Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
K36 Therapeutics, Inc.
Eli Lilly and Company
Pfizer
Alterome Therapeutics, Inc.
Massachusetts General Hospital
Eli Lilly and Company
Orca Biosystems, Inc.
Boston Scientific Corporation
VA Office of Research and Development
M.D. Anderson Cancer Center
Stemline Therapeutics, Inc.
Pfizer
DL Analytics
Rutgers, The State University of New Jersey
Cancer Research UK
Cancer Research UK
Pathos AI, Inc.
Corcept Therapeutics
Massachusetts General Hospital
Genelux Corporation
University of Pittsburgh
Plus Therapeutics
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Cogent Biosciences, Inc.
The First Affiliated Hospital of Guangzhou Medical University
Novartis
Endocyte